458 related articles for article (PubMed ID: 31970824)
1. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
2. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
3. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.
Freedberg DE; Lamousé-Smith ES; Lightdale JR; Jin Z; Yang YX; Abrams JA
Clin Infect Dis; 2015 Sep; 61(6):912-7. PubMed ID: 26060292
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
Freedberg DE; Salmasian H; Friedman C; Abrams JA
Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
[TBL] [Abstract][Full Text] [Related]
5. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Hospital-Acquired
Azab M; Doo L; Doo DH; Elmofti Y; Ahmed M; Cadavona JJ; Liu XB; Shafi A; Joo MK; Yoo JW
Gut Liver; 2017 Nov; 11(6):781-788. PubMed ID: 28506028
[TBL] [Abstract][Full Text] [Related]
7. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
8. Do the types and routes of proton pump inhibitor treatments affect
Lee P; Fike D; Yang H; Hall RG; Pass S; Alvarez CA
Expert Rev Clin Pharmacol; 2021 Mar; 14(3):399-404. PubMed ID: 33576287
[No Abstract] [Full Text] [Related]
9. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
12. Association of Clostridium difficile infections with acid suppression medications in children.
Nylund CM; Eide M; Gorman GH
J Pediatr; 2014 Nov; 165(5):979-84.e1. PubMed ID: 25112692
[TBL] [Abstract][Full Text] [Related]
13. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors versus histamine-2 receptor antagonists for stress ulcer prophylaxis during extracorporeal membrane oxygenation: a propensity score-matched analysis.
Kondo Y; Ohbe H; Matsui H; Fushimi K; Tanaka H; Yasunaga H
BMJ Open; 2020 Sep; 10(9):e037534. PubMed ID: 32994240
[TBL] [Abstract][Full Text] [Related]
15. Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis.
Mohammadi K; Yaribash S; Razi B; Dashti-Khavidaki S
J Clin Pharm Ther; 2022 May; 47(5):567-574. PubMed ID: 34931328
[TBL] [Abstract][Full Text] [Related]
16. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
Kwok CS; Arthur AK; Anibueze CI; Singh S; Cavallazzi R; Loke YK
Am J Gastroenterol; 2012 Jul; 107(7):1011-9. PubMed ID: 22525304
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
Barletta JF; Sclar DA
Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
[TBL] [Abstract][Full Text] [Related]
18. Risk of circulatory diseases associated with proton-pump inhibitors: a retrospective cohort study using electronic medical records in Thailand.
Pannoi T; Promchai C; Apiromruck P; Wongpraphairot S; Dong YH; Yang CC; Pan WC
PeerJ; 2024; 12():e16892. PubMed ID: 38371380
[TBL] [Abstract][Full Text] [Related]
19. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
